Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA2202DEQ" target="_blank" >RIV/61988987:17110/21:A2202DEQ - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/21:E0109068
Result on the web
<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000723882900001?SID=D3AcbN3VLEAItJrHohb" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000723882900001?SID=D3AcbN3VLEAItJrHohb</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21037/tlcr-20-1114" target="_blank" >10.21037/tlcr-20-1114</a>
Alternative languages
Result language
angličtina
Original language name
Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
Original language description
Background: Programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1) immune-checkpoint blockade is a promising new therapeutic strategy in cancer. However, expression patterns and prognostic significance of PD-L1 and PD-1 are still controversial in human malignant pleural mesothelioma (MPM). Methods: Formalin-fixed paraffin-embedded (FFPE) tumor samples from 203 MPM patients receiving standard treatment without immunotherapy were collected from 5 European centers. PD-L1 and PD-1 expression of tumor cells (TCs) and tumor-infiltrating lymphocytes (TILs) were measured by immunohistochemistry and correlated with clinical parameters and long-term outcome. Results: High (>10%) PD-L1 TC and PD-1 TILs expressions were found in 18 (8%) and 39 (24%) patients, respectively. PD-L1 was rarely expressed by TILs [>= 1%, n=13 (8%); >10%, n=1]. No significant associations were found between the PD-L1 or PD-1 expression of TCs or TILs and clinicopathological parameters such as stage or histological subtype. Notably, patients with high (>10%) TC-specific PD-L1 expression exhibited significantly worse median overall survival (OS) (6.3 vs. 15.1 months of those with low TC PD-L1 expression; HR: 2.51, P<0.001). In multivariate cox regression analysis adjusted for clinical parameters, high TC PD-L1 expression (>10%) proved to be an independent negative prognostic factor for OS (HR: 2.486, P=0.005). There was no significant correlation between PD-L1 or PD-1 expression of TILs and OS. Conclusions: In this multicenter cohort study, we demonstrate that high (>10%) PD-L1 expression of TCs independently predicts worse OS in MPM. Further studies are warranted to investigate the value of PD-L1/PD-1 expression as a marker for treatment response in MPM patients receiving immunotherapy.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Translational Lung Cancer Research
ISSN
2218-6751
e-ISSN
—
Volume of the periodical
10
Issue of the periodical within the volume
4
Country of publishing house
HK - HONG KONG
Number of pages
14
Pages from-to
1594-1607
UT code for WoS article
000723882900001
EID of the result in the Scopus database
—